At a glance
ClinicalIndex Comparison RecordN/ACompleted· 306 enrolled
Drug / intervention
MiniMed™ 780G Systemdevice
Likely dose
MiniMed™ 780G Systemfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France (EQOL Study)
In Brief
An observational study evaluating MiniMed™ 780G System for Type 1 Diabetes. Completed, enrolled 306 participants across 32 sites.
Detailed Summary
The purpose of the study is to evaluate the efficacy in glycemic control and the impact on the quality of life of patients using the MiniMed™ 780G System for the treatment of Type 1 diabetes, in real life settings in France.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartFeb 2021
Primary CompletionMay 2022
Study CompletionOct 2022
TodayJul 2026
First PostedMar 16, 2020
Enrollment StartFeb 15, 2021
Primary CompletionMay 19, 2022
Study CompletionOct 27, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.3 years ago
Interventions
MiniMed™ 780G Systemdevice
Subject enrolled in the study will start using the MiniMed™ 780G pump in Auto Mode after a run-in period of two weeks in Manual Mode (with no SmartGuard™ functions). Study phase in Automode will follow a 6 and 12 months follow- up as per standard of care.